Myeloma Pre-Printed Orders

File
pdf belantamab mafodotin-blmf 2.5 mg/kg Regimen (CP-0271) Jan 2023
pdf bortezomib 1.3 (maintenance) Regimen (CP-0307) Apr 2023
pdf bortezomib 1.3 lenalidomide 15 mg (RVD-Lite) Regimen Cycles 10-15 (CP-0262) Dec 2022
pdf bortezomib 1.3 lenalidomide 15 mg dexamethasone 40 mg (RVD-Lite) Regimen Cycles 1-9 (CP-0261) Dec 2022
pdf bortezomib 1.3 lenalidomide 25 mg dexamethasone 40 mg Regimen Cycles 1-8 (CP-0240) Nov 2022
pdf bortezomib 1.3 lenalidomide 25 mg dexamethasone 40 mg Regimen Cycles 9+ (CP-0239) Nov 2022
pdf bortezomib 1.3 selinexor 100 mg dexamethasone 40 mg compassionate Regimen (CP-0228) Nov 2022
pdf carfilzomib 20/27 lenalidomide 25 mg dexamethasone Regimen Cycle 1 (CP-0224) Jun 2022
pdf carfilzomib 20/70 cyclophosphamide 300 dexamethasone 40 mg Regimen Cycle 1 (CP-0220) Jun 2022
pdf carfilzomib 20/70 dexamethasone 40 mg Regimen Cycle 1 (CP-0301) Mar 2023
pdf carfilzomib 20/70 dexamethasone 40 mg Regimen Cycle 2+ (CP-0302) Mar 2023
pdf carfilzomib 27 lenalidomide 25 mg dexamethasone Regimen Cycles 13-18 (CP-0223) June 2022
pdf carfilzomib 27 lenalidomide 25 mg dexamethasone Regimen Cycles 2-12 (CP-0222) June 2022
pdf carfilzomib 70 cyclophosphamide 300 dexamethasone 40 mg Regimen Cycles 2+ (CP-0221) Jun 2022
pdf CyBorD Regimen Cycle 1 (CP-0226) Aug 2022
pdf CyBorD Regimen Cycles 2+ (CP-0229) Aug 2022
pdf cyclophosphamide 300 lenalidomide 25mg dexamethasone 40 mg Regimen Cycle 1 (CP-0335) May 2023
pdf cyclophosphamide 300 lenalidomide 25mg dexamethasone 40 mg Regimen Cycles 2+ (CP-0345) May 2023
pdf daratumumab IV 16 mg/kg lenalidomide 25 mg dexamethasone 40 mg Regimen Cycle 1 (CP-0278) July 2022
pdf daratumumab IV 16 mg/kg bortezomib 1.3 dexamethasone 20 mg (age and comorbidities) Regimen Cycle 1 (CP-0246) Jul 2022
pdf daratumumab IV 16 mg/kg bortezomib 1.3 dexamethasone 20 mg (age and comorbidities) Regimen Cycles 2 and 3 (CP-0247) Jul 2022
pdf daratumumab IV 16 mg/kg bortezomib 1.3 dexamethasone 20 mg (age and comorbidities) Regimen Cycles 4-8 (CP-0248) Jul 2022
pdf daratumumab IV 16 mg/kg bortezomib 1.3 dexamethasone 40 mg Regimen Cycle 1 (CP-0253) Jul 2022
pdf daratumumab IV 16 mg/kg bortezomib 1.3 dexamethasone 40 mg Regimen Cycles 2 and 3 (CP-0254) Jul 2022
pdf daratumumab IV 16 mg/kg bortezomib 1.3 dexamethasone 40 mg Regimen Cycles 4-8 (CP-0255) Jul 2022
pdf daratumumab IV 16 mg/kg cyclophosphamide 300 bortezomib 1.5 dexamethasone 20 mg (age and comorbidities) Multiple Myeloma Regimen Cycle 1 (CP-0265) Sept 2022
pdf daratumumab IV 16 mg/kg cyclophosphamide 300 bortezomib 1.5 dexamethasone 20 mg (age and comorbidities) Multiple Myeloma Regimen Cycle 2 (CP-0266) Sept 2022
pdf daratumumab IV 16 mg/kg cyclophosphamide 300 bortezomib 1.5 dexamethasone 20 mg (age and comorbidities) Multiple Myeloma Regimen Cycles 3-6 (CP-0267) Sept 2022
pdf daratumumab IV 16 mg/kg cyclophosphamide 300 bortezomib 1.5 dexamethasone 40 mg Multiple Myeloma Regimen Cycle 1 (CP-0257) Sept 2022
pdf daratumumab IV 16 mg/kg cyclophosphamide 300 bortezomib 1.5 dexamethasone 40 mg Multiple Myeloma Regimen Cycle 2 (CP-0258) Sept 2022
pdf daratumumab IV 16 mg/kg cyclophosphamide 300 bortezomib 1.5 dexamethasone 40 mg Multiple Myeloma Regimen Cycles 7-8 (CP-0263) Sept 2022
pdf daratumumab IV 16 mg/kg lenalidomide 25 mg dexamethasone 20 mg (age and comorbidities) Regimen Cycle 1 (CP-0394) July 2022
pdf daratumumab IV 16 mg/kg lenalidomide 25 mg dexamethasone 20 mg (age and comorbidities) Regimen Cycle 2 (CP-0395) July 2022
pdf daratumumab IV 16 mg/kg lenalidomide 25 mg dexamethasone 20 mg (age and comorbidities) Regimen Cycles 3-6 (CP-0396) July 2022
pdf daratumumab IV 16 mg/kg lenalidomide 25 mg dexamethasone 20 mg (age and comorbidities) Regimen Cycles 7+ (CP-0397) July 2022
pdf daratumumab IV 16 mg/kg lenalidomide 25 mg dexamethasone 40 mg Regimen Cycle 2 (CP-0279) July 2022
pdf daratumumab IV 16 mg/kg lenalidomide 25 mg dexamethasone 40 mg Regimen Cycles 3-6 (CP-0280) July 2022
pdf daratumumab IV 16 mg/kg lenalidomide 25 mg dexamethasone 40 mg Regimen Cycles 7+ (CP-0281) July 2022
pdf daratumumab IV 16mg/kg (Maintenance) Regimen (CP-0277) July 2022
pdf daratumumab IV 16mg/kg cyclophosphamide 300 bortezomib 1.5 dexamethasone 20 mg (age and comorbidities) Multiple Myeloma Regimen Cycles 9+ (CP-0269) Sept 2022
pdf daratumumab IV 16mg/kg cyclophosphamide 300 bortezomib 1.5 dexamethasone 20mg (age and comorbidities) Multiple Myeloma Regimen Cycles 7-8 (CP-0268) Sept 2022
pdf daratumumab IV 16mg/kg cyclophosphamide 300 bortezomib 1.5 dexamethasone 40 mg Multiple Myeloma Regimen Cycles 3-6 (CP-0259) Sept 2022
pdf daratumumab IV 16mg/kg cyclophosphamide 300 bortezomib 1.5 dexamethasone 40mg Multiple Myeloma Regimen Cycles 9+ (CP-0264) Sept 2022
pdf daratumumab SC 1800 mg bortezomib 1.3 dexamethasone 20 mg (age and comorbidities) Regimen Cycles 4-8 (CP-0380) Jul 2023
pdf daratumumab SC 1800 mg bortezomib 1.3 dexamethasone 20 mg (age and comorbidities) Regimen Cycle 1 (CP-0378) Jul 2023
pdf daratumumab SC 1800 mg bortezomib 1.3 dexamethasone 20 mg (age and comorbidities) Regimen Cycle 2-3 (CP-0379) Jul 2023
pdf daratumumab SC 1800 mg bortezomib 1.3 dexamethasone 40 mg Regimen Cycle 1 (CP-0375) Jul 2023
pdf daratumumab SC 1800 mg bortezomib 1.3 dexamethasone 40 mg Regimen Cycle 2-3 (CP-0376) Jul 2023
pdf daratumumab SC 1800 mg bortezomib 1.3 dexamethasone 40 mg Regimen Cycles 4-8 (CP-0377) Jul 2023
pdf daratumumab SC 1800 mg cyclophosphamide 300 bortezomib 1.5 dexamethasone 20 mg (age and comorbidities) Multiple Myeloma Regimen Cycles 3-6 (CP-0233) Aug 2022
pdf daratumumab SC 1800 mg cyclophosphamide 300 bortezomib 1.5 dexamethasone 20 mg (age and comorbidities) Multiple Myeloma Regimen Cycle 1 (CP-0231) Aug 2022
pdf daratumumab SC 1800 mg cyclophosphamide 300 bortezomib 1.5 dexamethasone 20 mg (age and comorbidities) Multiple Myeloma Regimen Cycle 2 (CP-0232) Aug 2022
pdf daratumumab SC 1800 mg cyclophosphamide 300 bortezomib 1.5 dexamethasone 20 mg (age and comorbidities) Multiple Myeloma Regimen Cycles 7-8 (CP-0234) Aug 2022
pdf daratumumab SC 1800 mg cyclophosphamide 300 bortezomib 1.5 dexamethasone 20 mg (age and comorbidities) Multiple Myeloma Regimen Cycles 9+ (CP-0230) Aug 2022
pdf daratumumab SC 1800 mg cyclophosphamide 300 bortezomib 1.5 dexamethasone 40 mg Multiple Myeloma Regimen Cycles 7-8 (CP-0244) Aug 2022
pdf daratumumab SC 1800 mg cyclophosphamide 300 bortezomib 1.5 dexamethasone 40 mg Multiple Myeloma Regimen Cycles 9+ (CP-0245) Aug 2022
pdf daratumumab SC 1800 mg cyclophosphamide 300 bortezomib 1.5 dexamethasone 40 mg Multiple Myeloma Regimen Cycle 1 (CP-0241) Aug 2022
pdf daratumumab SC 1800 mg cyclophosphamide 300 bortezomib 1.5 dexamethasone 40 mg Multiple Myeloma Regimen Cycle 2 (CP-0242) Aug 2022
pdf daratumumab SC 1800 mg cyclophosphamide 300 bortezomib 1.5 dexamethasone 40 mg Multiple Myeloma Regimen Cycles 3-6 (CP-0243) Aug 2022
pdf daratumumab SC 1800 mg lenalidomide 25 mg dexamethasone 20 mg (age and comorbidities) Regimen Cycle 1 (CP-0389) Aug 2023
pdf daratumumab SC 1800 mg lenalidomide 25 mg dexamethasone 20 mg (age and comorbidities) Regimen Cycle 2 (CP-0390) Aug 2023
pdf daratumumab SC 1800 mg lenalidomide 25 mg dexamethasone 20 mg (age and comorbidities) Regimen Cycles 3-6 (CP-0391) Aug 2023
pdf daratumumab SC 1800 mg lenalidomide 25 mg dexamethasone 20 mg (age and comorbidities) Regimen Cycles 7+ (CP-0392) Aug 2023
pdf daratumumab SC 1800 mg lenalidomide 25 mg dexamethasone 40 mg Regimen Cycle 2 (CP-0386) Aug 2023
pdf daratumumab SC 1800 mg lenalidomide 25 mg dexamethasone 40 mg Regimen Cycle 1 (CP-0385) Aug 2023
pdf daratumumab SC 1800 mg lenalidomide 25 mg dexamethasone 40 mg Regimen Cycles 3-6 (CP-0387) Aug 2023
pdf daratumumab SC 1800 mg lenalidomide 25 mg dexamethasone 40 mg Regimen Cycles 7+ (CP-0388) Aug 2023
pdf daratumumab-hyaluronidase 1800 mg cyclophosphamide 300 bortezomib 1.3 dexamethasone 20 mg Amyloidosis (age & comorbidities) Regimen Cycle 2 (CP-0446) January 2024
pdf daratumumab-hyaluronidase 1800 mg cyclophosphamide 300 bortezomib 1.3 dexamethasone 20 mg Amyloidosis (age & comorbidities) Regimen Cycles 3-6 (CP-0447) January 2024
pdf daratumumab-hyaluronidase 1800 mg cyclophosphamide 300 bortezomib 1.3 dexamethasone 20 mg Amyloidosis (age & comorbidities) Regimen Cycles 7 + (CP-0448) January 2024
pdf daratumumab-hyaluronidase 1800 mg cyclophosphamide 300 bortezomib 1.3 dexamethasone 20 mg Amyloidosis age & comorbidities Regimen Cycle 1 (CP-0445) January 2024
pdf daratumumab-hyaluronidase 1800 mg cyclophosphamide 300 bortezomib 1.3 dexamethasone 40 mg Amyloidosis Regimen Cycle 2 (CP-0274) January 2024
pdf daratumumab-hyaluronidase 1800 mg cyclophosphamide 300 bortezomib 1.3 dexamethasone 40 mg Amyloidosis Regimen Cycles 3-6 (CP-0275) January 2024
pdf daratumumab-hyaluronidase 1800 mg cyclophosphamide 300 bortezomib 1.3 dexamethasone 40 mg Amyloidosis Regimen Cycles 7 + (CP-0276) January 2024
pdf daratumumab-hyaluronidase 1800 mg cyclophosphamide 300 bortezomib 1.3 dexamethasone 40 mg Regimen Amyloidosis Cycle 1 (CP-0273) January 2024
pdf isatuximab 10 mg/kg carfilzomib 20/70 dexamethasone Regimen Cycle 1 (CP-0328) May 2023
pdf isatuximab 10 mg/kg carfilzomib 70 dexamethasone Regimen Cycles 2+ (CP-0329) May 2023
pdf isatuximab 10 mg/kg pomalidomide 4 mg dexamethasone 20 mg Regimen Cycle 1 (CP-0455) February 2024
pdf isatuximab 10 mg/kg pomalidomide 4 mg dexamethasone 40 mg Regimen Cycle 1 (CP-0324) February 2024
pdf isatuximab 10 mg/kg pomalidomide 4 mg dexamethasone 40 mg Regimen Cycles 2 + (CP-0325) February 2024
pdf isatuximab 10 mgkg pomalidomide 4 mg dexamethasone 20 mg Regimen Cycles 2 + (CP-0456) February 2024
pdf ixazomib 4 mg lenalidomide 25 mg dexamethasone 40 mg Regimen (CP-0272) Jan 2023
pdf lenalidomide 10 mg Regimen (CP-0256) Nov 2022
pdf lenalidomide 25 mg dexamethasone 40 mg Regimen (CP-0227) Nov 2022
pdf lenalidomide 5 mg Regimen (CP-0416) October 2023
pdf pomalidomide 4 mg cyclophosphamide 400 mg dexamethasone 40 mg Regimen Cycle 1 (CP-0344) Jun 2023
pdf pomalidomide 4 mg cyclophosphamide 400 mg dexamethasone 40 mg Regimen Cycles 2+ (CP-0350) Jun 2023
pdf pomalidomide 4mg dexamethasone 40mg Regimen (CP-0342) June 2023
Share This Page:
Last updated: 2024-01-03